{"hands_on_practices": [{"introduction": "A fundamental principle in cancer pathology is that tumors are often heterogeneous, containing areas with different degrees of aggressiveness. This exercise [@problem_id:4328901] challenges you to apply the crucial rule of grading based on the most aggressive features identified, a concept that directly impacts patient prognosis and treatment. Understanding why the final, comprehensive analysis of permanent sections overrides a preliminary intraoperative assessment is key to grasping the realities of tissue sampling and tumor biology.", "problem": "A 65-year-old patient undergoes resection of a supratentorial infiltrative glial tumor. An intraoperative frozen section shows a highly cellular astrocytic neoplasm with nuclear atypia and scattered mitoses, but no necrosis is appreciated on the limited frozen material. On permanent paraffin sections sampled from multiple blocks, there are unequivocal foci of pseudopalisading necrosis and areas of microvascular proliferation. Based on widely accepted tumor grading principles in neuropathology—specifically, that the World Health Organization (WHO) Central Nervous System (CNS) tumor grading system ranks diffuse astrocytic tumors by histologic features of biological aggressiveness such as mitotic activity, microvascular proliferation, and necrosis—choose the grading approach that most accurately reflects the biologic potential of the tumor and the realities of tissue sampling.\n\nWhich option best describes how the final grade should be assigned?\n\nA. Assign a final diagnosis consistent with astrocytoma, WHO grade 2, because the intraoperative frozen section lacked necrosis and freezing artifact can create spurious necrosis on permanent sections.\n\nB. Average the grades across all blocks to account for sampling heterogeneity; if some blocks show necrosis and others do not, assign an intermediate WHO grade 3.\n\nC. Base the final grade on the highest-grade histologic feature identified anywhere in the tumor on permanent sections; pseudopalisading necrosis mandates a final diagnosis consistent with glioblastoma, WHO grade 4.\n\nD. Maintain an astrocytoma, WHO grade 3, unless necrosis is corroborated by molecular alterations; necrosis observed only on permanent sections should not change the grade without matching intraoperative findings.", "solution": "The user wants me to act as a meticulous STEM professor and solve a pathology problem.\n\n### PROBLEM VALIDATION\n\n**Step 1: Extract Givens**\n\n*   Patient age: 65-year-old\n*   Tumor type and location: Supratentorial infiltrative glial tumor.\n*   Intraoperative frozen section findings:\n    *   Highly cellular astrocytic neoplasm\n    *   Nuclear atypia\n    *   Scattered mitoses\n    *   No necrosis appreciated.\n*   Permanent paraffin section findings (from multiple blocks):\n    *   Unequivocal foci of pseudopalisading necrosis\n    *   Areas of microvascular proliferation.\n*   Stated Principle: The World Health Organization (WHO) Central Nervous System (CNS) tumor grading system ranks diffuse astrocytic tumors by histologic features of biological aggressiveness, such as mitotic activity, microvascular proliferation, and necrosis.\n*   Question: Choose the grading approach that most accurately reflects the biologic potential of the tumor and the realities of tissue sampling.\n\n**Step 2: Validate Using Extracted Givens**\n\n1.  **Scientific Grounding**: The problem is well-grounded in the established principles of neuropathology and the WHO Classification of Tumours of the Central Nervous System. The concepts of frozen section versus permanent section, tumor heterogeneity, histologic features (nuclear atypia, mitoses, microvascular proliferation, pseudopalisading necrosis), and their use in grading diffuse astrocytic gliomas are standard and factually correct. The scenario presents a classic diagnostic challenge.\n2.  **Well-Posed**: The problem is well-posed. It provides a clear set of histologic findings from different sampling modalities and asks for the application of a well-defined, standard-of-care grading principle. A unique, correct answer based on established medical practice exists.\n3.  **Objective**: The problem is stated in objective, clinical language, describing microscopic findings without ambiguity or subjective bias.\n\nThe problem statement is internally consistent. The discrepancy between the frozen section and permanent section findings is not a contradiction but the central point of the question, testing the understanding of sampling error and the hierarchy of diagnostic evidence in pathology. The problem is valid.\n\n**Step 3: Verdict and Action**\n\nThe problem is valid. I will proceed with the solution.\n\n### SOLUTION\n\nThe fundamental principle in the pathologic grading of infiltrative gliomas, such as astrocytomas, is that the final grade assigned to the tumor must reflect its highest degree of anaplasia and most aggressive biological potential. This is because tumor behavior, patient prognosis, and subsequent therapeutic management are determined by the most malignant-appearing component of the neoplasm. Tumors are often heterogeneous, meaning different areas can display features of different grades. A limited sample, such as a biopsy or an intraoperative frozen section, may not be representative of the entire tumor.\n\nThe World Health Organization (WHO) grading for diffuse astrocytic tumors in adults is based on a combination of histologic and, in the modern era, molecular features. For the purpose of this problem, which focuses on histology, we consider the classical criteria for IDH-wildtype tumors, which are most common in this age group (65 years).\n\n*   **WHO Grade 2 (diffuse astrocytoma)**: Characterized by nuclear atypia alone.\n*   **WHO Grade 3 (anaplastic astrocytoma)**: Characterized by nuclear atypia and significant mitotic activity.\n*   **WHO Grade 4 (glioblastoma)**: Characterized by nuclear atypia, mitotic activity, and the presence of either microvascular proliferation or necrosis (or both). The presence of pseudopalisading necrosis is a pathognomonic feature of glioblastoma.\n\nLet's analyze the findings in this case:\n1.  **Intraoperative Frozen Section**: This is a rapid, preliminary assessment performed on a small piece of tissue. The findings of a \"highly cellular astrocytic neoplasm with nuclear atypia and scattered mitoses\" suggest at least a WHO grade 3 tumor. The absence of necrosis in this limited sample is a common occurrence due to sampling error. The purpose of a frozen section is to provide a preliminary diagnosis to the surgeon (e.g., to confirm the presence of a tumor), not to render a final, definitive grade.\n\n2.  **Permanent Paraffin Sections**: This is the gold standard for diagnosis. It involves processing the entire resected specimen, or at least multiple, representative blocks of it, with superior fixation and staining, resulting in high-quality microscopic detail. The problem states that these sections, sampled from \"multiple blocks,\" showed \"unequivocal foci of pseudopalisading necrosis and areas of microvascular proliferation.\"\n\nAccording to the WHO grading criteria, the presence of either microvascular proliferation or necrosis in a diffuse astrocytic glioma is sufficient to classify it as WHO grade 4. This case presents both. The final diagnosis must be based on these definitive, highest-grade findings from the permanent sections. The lower-grade features seen on the frozen section are superseded.\n\n### Option-by-Option Analysis\n\n**A. Assign a final diagnosis consistent with astrocytoma, WHO grade 2, because the intraoperative frozen section lacked necrosis and freezing artifact can create spurious necrosis on permanent sections.**\nThis option is fundamentally flawed. Firstly, the diagnosis must be based on the permanent sections, which are the gold standard, not the limited intraoperative consultation. Secondly, a tumor with \"scattered mitoses\" is, by definition, at least a WHO grade 3, not grade 2. Thirdly, the problem explicitly states \"unequivocal foci of pseudopalisading necrosis,\" which means a competent pathologist has already ruled out artifact.\n**Verdict: Incorrect.**\n\n**B. Average the grades across all blocks to account for sampling heterogeneity; if some blocks show necrosis and others do not, assign an intermediate WHO grade 3.**\nThis approach is a grave violation of a core principle of cancer pathology. Tumor grading is not an averaging process. The biologic behavior of the tumor is dictated by its most aggressive component. A tumor containing any volume of grade 4 features behaves as a grade 4 tumor. Assigning an intermediate grade would be dangerously misleading and would lead to undertreatment.\n**Verdict: Incorrect.**\n\n**C. Base the final grade on the highest-grade histologic feature identified anywhere in the tumor on permanent sections; pseudopalisading necrosis mandates a final diagnosis consistent with glioblastoma, WHO grade 4.**\nThis option correctly states the guiding principle of glioma grading. The final grade is determined by the highest-grade features found after examining all available tissue. In this case, the definitive finding of pseudopalisading necrosis (and microvascular proliferation) on the permanent sections elevates the diagnosis to WHO grade 4. For a diffuse astrocytic glioma in a 65-year-old, this corresponds to a diagnosis of glioblastoma, IDH-wildtype, WHO grade 4.\n**Verdict: Correct.**\n\n**D. Maintain an astrocytoma, WHO grade 3, unless necrosis is corroborated by molecular alterations; necrosis observed only on permanent sections should not change the grade without matching intraoperative findings.**\nThis option is incorrect for two primary reasons. First, histologic findings of necrosis or microvascular proliferation are, in themselves, sufficient criteria for a WHO grade 4 diagnosis; they do not require molecular corroboration. While molecular markers can independently establish a grade 4 diagnosis in the absence of these histologic features, they are not required when the histology is already definitively grade 4. Second, the idea that permanent section findings must be supported by intraoperative findings is logically inverted; the permanent section is the definitive analysis that supersedes the preliminary frozen section.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{C}$$", "id": "4328901"}, {"introduction": "Modern glioma classification relies heavily on molecular markers to define tumor entities, moving beyond purely microscopic appearance. This practice problem [@problem_id:4328927] simulates a common diagnostic scenario, requiring you to synthesize multiple immunohistochemical results to distinguish a specific low-grade astrocytoma from its mimics. Correctly interpreting markers for p53 and ATRX is essential for identifying the IDH-mutant astrocytoma pathway and guiding patient care.", "problem": "A 35-year-old patient presents with a slowly enlarging, nonenhancing cortical lesion. Histology shows mild hypercellularity of astrocytic cells with no necrosis or microvascular proliferation. Immunohistochemistry demonstrates strong diffuse nuclear staining for p53, complete loss of nuclear expression of Alpha Thalassemia/Mental Retardation Syndrome X-linked (ATRX), robust cytoplasmic staining for Glial Fibrillary Acidic Protein (GFAP), and a $Ki\\text{-}67$ labeling index of approximately $3\\%$. Based on foundational definitions of neoplasia versus reactive processes and well-established interpretive principles of immunohistochemistry in neuropathology, which single interpretation best integrates these findings, and why?\n\nA. Reactive gliosis, because GFAP positivity and low $Ki\\text{-}67$ are expected in non-neoplastic reactive astrocytes.\n\nB. Oligodendroglioma, isocitrate dehydrogenase (IDH)-mutant with $1p/19q$ codeletion, because low $Ki\\text{-}67$ and p53 overexpression favor a low-grade glioma.\n\nC. Diffuse astrocytoma, isocitrate dehydrogenase (IDH)-mutant, because p53 overexpression and ATRX loss indicate a clonal astrocytic neoplasm rather than a reactive process.\n\nD. Glioblastoma, IDH-wildtype, because GFAP positivity and abnormal p53 expression are common in high-grade astrocytic tumors.\n\nE. Pilocytic astrocytoma, because low $Ki\\text{-}67$ and GFAP positivity suggest a circumscribed low-grade astrocytoma.", "solution": "The problem statement is valid. It presents a coherent and scientifically sound clinical and pathological scenario that is internally consistent and well-posed, allowing for a rigorous diagnostic interpretation based on established principles of neuropathology. The data are sufficient and relevant to the question asked.\n\nThe solution requires an integrated analysis of the clinical, histological, and immunohistochemical findings in the context of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System.\n\n**Analysis of Given Information**\n\n1.  **Clinical and Radiological Data:** A 35-year-old patient with a slowly enlarging, nonenhancing cortical lesion.\n    -   The age of 35 is typical for the presentation of adult-type diffuse gliomas.\n    -   \"Slowly enlarging\" suggests a low-grade process.\n    -   \"Nonenhancing\" (i.e., no contrast enhancement on imaging) indicates an intact blood-brain barrier, which is characteristic of low-grade gliomas (WHO CNS grades 2). High-grade gliomas (grades 3 and 4) typically exhibit contrast enhancement due to breakdown of the blood-brain barrier associated with microvascular proliferation.\n\n2.  **Histological Data:** Mild hypercellularity of astrocytic cells with no necrosis or microvascular proliferation.\n    -   \"Mild hypercellularity\" and the infiltrative nature implied by a \"cortical lesion\" are features of a diffuse glioma.\n    -   The explicit absence of \"necrosis\" and \"microvascular proliferation\" are critical findings. These are high-grade features, and their absence is required for a diagnosis of a low-grade diffuse glioma (WHO CNS grade 2).\n\n3.  **Immunohistochemical (IHC) Data:**\n    -   **Glial Fibrillary Acidic Protein (GFAP):** \"Robust cytoplasmic staining for GFAP\" confirms the astrocytic lineage of the tumor cells. GFAP is an intermediate filament protein found in astrocytes and is a canonical marker for astrocytic neoplasms. However, reactive astrocytes also stain for GFAP, so this finding alone does not distinguish a neoplasm from reactive gliosis.\n    -   **$Ki\\text{-}67$ Labeling Index:** An index of approximately $3\\%$ indicates a low proliferative activity. This is consistent with a low-grade neoplasm (WHO CNS grade 2) or a reactive process. It argues against a high-grade neoplasm, which would typically have a much higher index (e.g., $>10\\%-15\\%$).\n    -   **p53 Protein:** \"Strong diffuse nuclear staining for p53\" is a pivotal finding. The p53 protein, encoded by the tumor suppressor gene TP53, has a very short half-life in its wild-type form and is not detectable by standard IHC. Mutations in the TP53 gene often lead to a conformationally altered, stabilized protein that accumulates in the nucleus, resulting in this strong, diffuse staining pattern. Therefore, this finding is a surrogate marker for a TP53 mutation, which is a hallmark of a clonal, neoplastic process. Reactive cells do not harbor TP53 mutations and do not show this pattern. This result strongly argues against reactive gliosis.\n    -   **Alpha Thalassemia/Mental Retardation Syndrome X-linked (ATRX) Protein:** \"Complete loss of nuclear expression of ATRX\" is another key molecular finding. The ATRX protein is involved in chromatin remodeling. Loss of its nuclear expression (while internal controls like endothelial cells remain positive) is a reliable IHC surrogate for an inactivating mutation in the ATRX gene.\n\n**Synthesis and Diagnosis**\n\nThe diagnosis of adult-type diffuse gliomas is based on an integrated assessment of histology and molecular markers.\n- The combination of a TP53 mutation (inferred from p53 overexpression) and an ATRX mutation (inferred from ATRX loss) is the defining molecular signature of an **isocitrate dehydrogenase (IDH)-mutant astrocytoma**.\n- According to the WHO classification, diffuse gliomas are first stratified by IDH status. The presence of ATRX loss is almost perfectly correlated with IDH mutation.\n- Within the IDH-mutant gliomas, there are two main branches:\n    1.  **Astrocytoma, IDH-mutant:** Characterized by ATRX loss and TP53 mutation.\n    2.  **Oligodendroglioma, IDH-mutant and $1p/19q$-codeleted:** Characterized by intact ATRX expression and codeletion of chromosome arms 1p and 19q.\n- The finding of ATRX loss in this case places the tumor definitively in the astrocytic lineage and excludes oligodendroglioma.\n- The histological grade is determined by features like mitotic activity, and the presence of necrosis or microvascular proliferation. The absence of necrosis and microvascular proliferation, combined with a low $Ki\\text{-}67$ index of $3\\%$, establishes this tumor as a **WHO CNS grade 2** lesion.\n\nTherefore, the integrated diagnosis is a **Diffuse Astrocytoma, IDH-mutant, WHO CNS grade 2**.\n\n**Evaluation of Options**\n\n-   **A. Reactive gliosis, because GFAP positivity and low $Ki\\text{-}67$ are expected in non-neoplastic reactive astrocytes.**\n    **Incorrect.** This interpretation completely ignores the most critical findings: strong diffuse p53 nuclear staining and complete loss of ATRX nuclear expression. These two markers indicate clonal mutations in the TP53 and ATRX genes, respectively, which are definitive evidence of a neoplasm, not a reactive process.\n\n-   **B. Oligodendroglioma, isocitrate dehydrogenase (IDH)-mutant with $1p/19q$ codeletion, because low $Ki\\text{-}67$ and p53 overexpression favor a low-grade glioma.**\n    **Incorrect.** The diagnosis of oligodendroglioma requires the presence of a 1p/19q codeletion and, by molecular definition, intact ATRX expression. The finding of \"complete loss of nuclear expression of ATRX\" is mutually exclusive with a diagnosis of oligodendroglioma.\n\n-   **C. Diffuse astrocytoma, isocitrate dehydrogenase (IDH)-mutant, because p53 overexpression and ATRX loss indicate a clonal astrocytic neoplasm rather than a reactive process.**\n    **Correct.** This option correctly identifies the tumor type and grade based on the synthesis of all available data. The reasoning provided is precisely correct: the combination of p53 overexpression (surrogate for TP53 mutation) and ATRX loss (surrogate for ATRX mutation) serves as the molecular fingerprint for an IDH-mutant astrocytoma. These findings definitively establish the process as a clonal neoplasm. The other findings (age, clinical presentation, histology, low $Ki\\text{-}67$) are all consistent with this being a low-grade (WHO CNS grade 2) diffuse astrocytoma.\n\n-   **D. Glioblastoma, IDH-wildtype, because GFAP positivity and abnormal p53 expression are common in high-grade astrocytic tumors.**\n    **Incorrect.** This is a high-grade (WHO CNS grade 4) diagnosis. The problem explicitly states there is \"no necrosis or microvascular proliferation,\" and the $Ki\\text{-}67$ index is low ($3\\%$). These findings are incompatible with a diagnosis of glioblastoma. Furthermore, while some IDH-wildtype glioblastomas may have p53 alterations, the specific combination of ATRX loss with p53 mutation is the signature of the IDH-mutant pathway, not the IDH-wildtype pathway.\n\n-   **E. Pilocytic astrocytoma, because low $Ki\\text{-}67$ and GFAP positivity suggest a circumscribed low-grade astrocytoma.**\n    **Incorrect.** Pilocytic astrocytoma is a WHO CNS grade 1 tumor that is typically well-circumscribed, not diffusely infiltrative. Most importantly, it has a different molecular genetic basis, commonly involving alterations in the MAPK pathway (e.g., BRAF fusion or mutation). It is not defined by ATRX or TP53 mutations. The finding of ATRX loss rules out this diagnosis.", "answer": "$$\\boxed{C}$$", "id": "4328927"}, {"introduction": "The latest WHO classification of brain tumors introduced a paradigm-shifting concept: some tumors are classified as the highest grade based on their molecular signature alone, even if they lack the classic high-grade microscopic features. This exercise [@problem_id:4328912] tests your understanding of this advanced principle, specifically how the presence of a TERT promoter mutation in an IDH-wildtype astrocytoma is a defining feature of glioblastoma. This illustrates how genetics can directly dictate a diagnosis and predict aggressive behavior, overriding traditional histology.", "problem": "An adult patient aged 56 years presents with a diffusely infiltrative right frontal lobe tumor. Magnetic Resonance Imaging (MRI) shows a nonenhancing, $T_2$-hyperintense mass without radiologic necrosis. Resection reveals a diffuse astrocytic neoplasm composed of moderately pleomorphic glial cells with increased cellularity and mitotic figures but no microvascular proliferation and no necrosis on extensive sampling. Immunohistochemistry shows that isocitrate dehydrogenase (IDH) R$132$H is negative, with retained Alpha Thalassemia/Mental Retardation Syndrome X-Linked (ATRX) expression and low p53 labeling. Targeted next-generation sequencing detects a telomerase reverse transcriptase (TERT) promoter hotspot mutation designated c.-124C>T (also known as C228T). Copy-number profiling shows no epidermal growth factor receptor (EGFR) amplification and no combined whole chromosome $+7/-10$ signature. \n\nUsing the World Health Organization (WHO) $2021$ Central Nervous System (CNS) classification framework for adult-type diffuse gliomas, which of the following is the most appropriate integrated diagnosis and rationale?\n\nA. Glioblastoma, IDH-wildtype, WHO grade $4$, because in an adult IDH-wildtype diffuse astrocytic tumor, a TERT promoter hotspot mutation fulfills molecular criteria for glioblastoma even without histologic grade $4$ features.\n\nB. Diffuse astrocytoma, IDH-wildtype, WHO grade $2$, because the absence of necrosis and microvascular proliferation precludes a grade $4$ diagnosis regardless of molecular findings.\n\nC. Diffuse astrocytoma, IDH-wildtype, WHO grade $3$, because a TERT promoter mutation upgrades the tumor by one grade but does not reach the threshold for glioblastoma.\n\nD. Oligodendroglioma, IDH-wildtype, WHO grade $2$, because a TERT promoter mutation indicates oligodendroglial lineage irrespective of IDH status.\n\nE. Glioblastoma, IDH-wildtype, WHO grade $4$, but only if EGFR is amplified or combined whole chromosome $+7/-10$ is present in addition to the TERT promoter mutation; TERT alone is insufficient.", "solution": "## PROBLEM VALIDATION\n\n### Step 1: Extract Givens\nThe problem provides the following information:\n-   **Patient**: An adult aged 56 years.\n-   **Tumor Location and Type**: A diffusely infiltrative right frontal lobe tumor.\n-   **Radiology (MRI)**: A non-enhancing, $T_2$-hyperintense mass without radiologic necrosis.\n-   **Histopathology**:\n    -   Diagnosis: Diffuse astrocytic neoplasm.\n    -   Features: Moderately pleomorphic glial cells, increased cellularity, mitotic figures.\n    -   Negative afeatures: No microvascular proliferation, no necrosis on extensive sampling.\n-   **Immunohistochemistry (IHC)**:\n    -   Isocitrate dehydrogenase (IDH): IDH R$132$H is negative.\n    -   Alpha Thalassemia/Mental Retardation Syndrome X-Linked (ATRX): Retained expression.\n    -   p53: Low labeling.\n-   **Molecular Genetics**:\n    -   Targeted next-generation sequencing: Telomerase reverse transcriptase (TERT) promoter hotspot mutation designated c.-124C>T (also known as C228T).\n    -   Copy-number profiling: No epidermal growth factor receptor (EGFR) amplification.\n    -   Copy-number profiling: No combined whole chromosome $+7/-10$ signature.\n-   **Framework**: The diagnosis must be made using the World Health Organization (WHO) $2021$ Central Nervous System (CNS) classification framework for adult-type diffuse gliomas.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded**: The problem is firmly grounded in the fields of neuropathology and neuro-oncology. All terms used—such as `diffuse astrocytoma`, `IDH`, `ATRX`, `TERT`, `EGFR`, `+7/-10`, `WHO 2021 CNS classification`, `microvascular proliferation`, and `necrosis`—are standard and accurately represent current diagnostic practice. The clinical and pathological scenario described is entirely plausible.\n2.  **Well-Posed**: The problem is well-posed. It provides a detailed and specific set of clinical, histological, and molecular data. The question asks for the most appropriate integrated diagnosis based on a single, well-defined classification system (WHO $2021$), which provides a clear algorithm for arriving at a unique solution.\n3.  **Objective**: The language is objective and free of subjective or ambiguous statements. The findings are presented as factual observations from standard diagnostic tests.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. It is scientifically sound, well-posed, objective, and provides sufficient information to derive a unique diagnosis based on the specified classification system. The solution process may proceed.\n\n## DERIVATION OF SOLUTION\n\nThe diagnosis of adult-type diffuse gliomas under the WHO $2021$ classification follows a layered, integrated approach, prioritizing molecular markers over traditional histology in certain contexts. The diagnostic algorithm proceeds as follows:\n\n1.  **Initial Categorization**: The patient is an adult (56 years) with a \"diffuse astrocytic neoplasm,\" placing the tumor within the category of adult-type diffuse gliomas.\n\n2.  **IDH Status Determination**: The first major branching point in the classification is the isocitrate dehydrogenase (IDH) mutation status. The problem states that IHC for the most common mutation, IDH R$132$H, is negative. In the diagnostic algorithm for adult-type diffuse gliomas, this finding is used to classify the tumor as IDH-wildtype. While sequencing would be definitive for all rare IDH1 and IDH2 mutations, the provided data points towards an IDH-wildtype entity. The retained ATRX expression is also consistent with either an oligodendroglioma or an IDH-wildtype astrocytoma, but not an IDH-mutant astrocytoma (which characteristically shows ATRX loss).\n\n3.  **Classification of IDH-wildtype Diffuse Astrocytomas**: For adult-type diffuse astrocytic gliomas that are IDH-wildtype, the WHO $2021$ classification has specific criteria. A tumor in this category is designated **Glioblastoma, IDH-wildtype, WHO grade $4$** if it meets the histological criteria for grade $4$ (necrosis and/or microvascular proliferation) **OR** if it displays any of the following key molecular alterations, even in the absence of grade $4$ histology:\n    -   TERT promoter mutation\n    -   EGFR gene amplification\n    -   Combined gain of entire chromosome $7$ and loss of entire chromosome $10$ ($+7/-10$ signature)\n\n4.  **Integration of Case Findings**:\n    -   The tumor is histologically a lower-grade diffuse astrocytoma. The presence of mitotic activity would suggest at least WHO grade $2$ and possibly grade $3$, but it critically lacks necrosis and microvascular proliferation, the histological hallmarks of grade $4$.\n    -   Molecularly, the tumor is IDH-wildtype.\n    -   The sequencing results show the presence of a TERT promoter hotspot mutation (c.-124C>T).\n    -   The tumor lacks EGFR amplification and the $+7/-10$ signature.\n\n5.  **Conclusion**: According to the WHO $2021$ rules, the presence of a TERT promoter mutation in an IDH-wildtype diffuse astrocytic glioma is sufficient, on its own, to establish the diagnosis of \"Glioblastoma, IDH-wildtype, WHO grade $4$.\" The molecular findings override the lower-grade histological appearance. This principle is a cornerstone of the modern classification, recognizing that tumors with these specific molecular features behave as aggressively as histologically high-grade tumors, and therefore should be classified and treated as such.\n\n## OPTION-BY-OPTION ANALYSIS\n\n**A. Glioblastoma, IDH-wildtype, WHO grade $4$, because in an adult IDH-wildtype diffuse astrocytic tumor, a TERT promoter hotspot mutation fulfills molecular criteria for glioblastoma even without histologic grade $4$ features.**\n-   **Analysis**: This statement is a precise and accurate application of the WHO $2021$ CNS classification criteria. The diagnosis, grade, and rationale are all correct. The TERT promoter mutation is one of the three stand-alone molecular markers that define an IDH-wildtype diffuse astrocytoma as a glioblastoma, WHO grade $4$, regardless of its histological features.\n-   **Verdict**: **Correct**.\n\n**B. Diffuse astrocytoma, IDH-wildtype, WHO grade $2$, because the absence of necrosis and microvascular proliferation precludes a grade $4$ diagnosis regardless of molecular findings.**\n-   **Analysis**: This statement is incorrect. It reflects an outdated, purely histological approach to glioma classification. The WHO $2021$ system explicitly states that specific molecular findings can and do override histology for grading and diagnosis. The absence of histologic grade $4$ features does not preclude a WHO grade $4$ diagnosis if the required molecular criteria are met. Furthermore, the presence of mitotic figures makes a grade $2$ diagnosis less likely than grade $3$ on a purely histologic basis.\n-   **Verdict**: **Incorrect**.\n\n**C. Diffuse astrocytoma, IDH-wildtype, WHO grade $3$, because a TERT promoter mutation upgrades the tumor by one grade but does not reach the threshold for glioblastoma.**\n-   **Analysis**: This statement is incorrect. The impact of a TERT promoter mutation in this context is not a simple \"one-grade upgrade.\" It is a specific, defining criterion for a WHO grade $4$ diagnosis. There is no rule in the WHO $2021$ classification that a TERT mutation merely increases the grade from $2$ to $3$; instead, it directly establishes the diagnosis of Glioblastoma, IDH-wildtype, WHO grade $4$.\n-   **Verdict**: **Incorrect**.\n\n**D. Oligodendroglioma, IDH-wildtype, WHO grade $2$, because a TERT promoter mutation indicates oligodendroglial lineage irrespective of IDH status.**\n-   **Analysis**: This statement is incorrect. The defining molecular signature of an oligodendroglioma is the combination of an IDH mutation and a 1p/19q co-deletion. This tumor is IDH-wildtype, which definitively excludes the diagnosis of oligodendroglioma. While TERT promoter mutations are nearly ubiquitous in oligodendrogliomas, they are not specific and are also a key feature of IDH-wildtype glioblastomas.\n-   **Verdict**: **Incorrect**.\n\n**E. Glioblastoma, IDH-wildtype, WHO grade $4$, but only if EGFR is amplified or combined whole chromosome $+7/-10$ is present in addition to the TERT promoter mutation; TERT alone is insufficient.**\n-   **Analysis**: This statement is incorrect. The WHO $2021$ criteria for molecularly defining a glioblastoma are disjunctive, not conjunctive. The presence of *any one* of the three alterations—TERT promoter mutation, EGFR amplification, or the $+7/-10$ signature—is sufficient. Requiring an additional marker alongside the TERT mutation is a misinterpretation of the diagnostic rule.\n-   **Verdict**: **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4328912"}]}